The past few years have been tough on biotech chief and "most hated man in America" Martin Shkreli after a 2017 fraud conviction landed him behind bars. Despite that sentence––and the hefty civil penalty that came with it––Shkreli isn't nearly out of the woods yet.

The Federal Trade Commission and New York attorney general filed a new lawsuit against Shkreli and Vyera Pharmaceuticals––formerly Turing––alleging a "comprehensive scheme" to stifle generic versions of its toxoplasmosis med Daraprim.

According to the lawsuit, Shkreli and Vyera put in place a "web of contractual restrictions" that stopped distributors from reselling Daraprim to generics makers to thwart the bioequivalance testing required by the FDA in developing copycat drugs.

The lawsuit presents a new challenge for Shkreli, who is serving out a five-year prison sentence as part of his 2017 federal fraud conviction.

In November, the U.S. Supreme Court denied hearing Shkreli's appeal to overturn that conviction as a result of his disastrous run as head of biotech Retrophin. Shkreli was also forced to forfeit $7.36 million.

With that final rebuff, Shkreli will likely see the inside of a jail cell for the next five years––a sentence that could grow longer after he was accused of running his business from behind bars.

In March, the Bureau of Prisons struck up an investigation into a Wall Street Journal report Shkreli was running his new biotech, Phoenixus AG, using a contraband cell phone.

A month later, the bureau announced it had moved Shkreli from the low-security prison in Fort Dix to the Metropolitan Detention Center in downtown Brooklyn, according to CNBC. The outlet said Shkreli would remain at that facility until he's transferred to a federal prison in Allenwood, Pennsylvania.

Shkreli came to infamy in 2015 after Turing––where Shkreli also served as CEO––raised Daraprim's price overnight. Instead of apologizing, explaining or reversing the hike, Shkreli hit back at critics, quickly gaining fame as the “most hated” man in America.

Later, Retrophin investors accused him of inflating the company's stock price and enriching himself on the proceeds.